Rydex S&P MidCap 400 Pure Growth Fund Class A RYMGX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 63.58  /  −0.34 %
  • Total Assets 33.2M
  • Adj. Expense Ratio
    1.540%
  • Expense Ratio 1.540%
  • Distribution Fee Level High
  • Share Class Type Front Load
  • Category Mid-Cap Growth
  • Investment Style Small Growth
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield 0.00
  • Turnover 716%

USD | NAV as of Jun 18, 2026 | 1-Day Return as of Jun 18, 2026, 12:11 AM GMT+0

Morningstar’s Analysis RYMGX

Will RYMGX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Rydex S&P MidCap 400 Pure Growth A holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYMGX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 19.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Medpace Holdings Inc

2.20 590,856
Healthcare

Halozyme Therapeutics Inc

2.13 574,338
Healthcare

Celsius Holdings Inc

1.96 527,702
Consumer Defensive

Talen Energy Corp Ordinary Shares New

1.95 525,901
Utilities

Woodward Inc

1.93 519,688
Industrials

Hecla Mining Co

1.91 514,522
Basic Materials

AeroVironment Inc

1.88 505,792
Industrials

EchoStar Corp Class A

1.86 501,324
Communication Services

Five Below Inc

1.78 479,941
Consumer Cyclical

Rambus Inc

1.74 467,444
Technology

Sponsor Center